Common use of Disclosure of Results of Research Program Clause in Contracts

Disclosure of Results of Research Program. The results of all work performed by a Party as part of the Research Program shall be promptly disclosed to the other Party in a reasonable manner as such results are obtained. Ambrx and BMS will provide reports and analyses at each JRC meeting, and more frequently upon reasonable request by the JRC, detailing the current status of the Research Program, including the utilization of the Ambrx FTE resources. Within thirty (30) days following the end of each calendar quarter, Ambrx and BMS shall each exchange and provide to the JRC a written report summarizing in reasonable detail the work performed by it under the Research Program and results achieved during the preceding calendar quarter. In addition, upon reasonable request by a Party, the other Party will make presentations to the JRC of its activities related to the Compounds and Products to inform such Party of the details of the work done in the performance of the Research Program. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Upon reasonable request by BMS, for purposes of supporting the Development of a Product, Ambrx shall provide BMS with additional data, results and other information with respect to the work performed by Ambrx in the performance of the Research Program. Any reports required under this Section 3.7 may take the form of and be recorded in minutes of the JRC that will contain copies of any slides relating to the results and presented to the JRC. In addition, at BMS’ request Ambrx will transfer (within thirty (30) days of such request) to BMS all data, results, and information related to testing and studies of the Compounds (including analytical test results and non-clinical pharmacology and safety data) in the possession of Ambrx to the extent such data, results and/or information are necessary or reasonably useful for the continued Development and Commercialization of Products, including any and all Information directly relating to manufacturing methods (including related analytical methods) of the Compounds or Products.

Disclosure of Results of Research Program. The results of all work performed by a Party as part of the Research Program shall be promptly disclosed to the other Party in a reasonable manner as such results are obtained. Ambrx and BMS will provide reports and analyses at each JRC meeting, and more frequently upon reasonable request by the JRC, detailing the current status of the Research Program, including the utilization of the Ambrx FTE resources. Within thirty (30) days following the end of each calendar quarterCalendar Quarter, Ambrx and BMS shall each exchange and provide to the JRC a written report summarizing in reasonable detail the work performed by it under the Research Program and results achieved during the preceding calendar quarterCalendar Quarter. In addition, upon reasonable request by a Party, the other Party will make presentations to the JRC of its activities related to the Compounds and Products to inform such Party of the details of the work done in the performance of the Research Program. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Upon reasonable request by BMS, for purposes of supporting the Development and/or Commercialization of a Product, Ambrx shall provide BMS with additional data, results and other information with respect to the work performed by Ambrx in the performance of the Research Program. Any reports required under this Section 3.7 may take the form of and be recorded in minutes of the JRC that will contain copies of any slides relating to the results and presented to the JRC. In addition, at BMS’ request Ambrx will transfer (within thirty (30) days of such request) to BMS all data, results, and information related to testing and studies of the Compounds (including analytical test results and non-clinical pharmacology and safety data) in the possession of Ambrx to the extent such data, results and/or information are necessary or reasonably useful for the continued Development and Commercialization of Products, including any and all Information directly relating to manufacturing methods (including related analytical methods) of the Compounds or Products.

Disclosure of Results of Research Program. The results of all work performed by a Party the Parties as part of the Research Program shall be promptly disclosed to the other Party in a reasonable manner as such results are obtained. Ambrx Pharmacopeia shall provide BMS monthly with reports of the work performed under the Research Program and the Research Results in a format acceptable to the Working Group and JRC. Pharmacopeia and BMS will provide reports and analyses at each JRC meeting, and more frequently upon on reasonable request by the JRC, detailing the current status of the Research Program, including but not limited to the utilization of the Ambrx FTE resourcesPharmacopeia Research Personnel. Within thirty (30) days following the end of each calendar quarterCalendar Quarter, Ambrx Pharmacopeia and BMS Alliance Managers and/or JRC members, as applicable, shall each exchange and provide to the JRC a written report in a mutually acceptable format summarizing in reasonable detail the work performed by it under the Research Program and results achieved during the preceding calendar quarter. In addition, upon reasonable request by a Party, the other Party will make presentations to the JRC of its activities related to the Compounds and Products to inform such Party of the details of the work done in the performance of the Research ProgramCalendar Quarter. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Upon reasonable request by BMS, for purposes of supporting the Development of a Product, Ambrx Pharmacopeia shall provide BMS with additional data, results and other information with respect to the work performed by Ambrx Pharmacopeia in the performance of the Research Program. Any reports required under this Section 3.7 3.11 may take the form of and be recorded in minutes of the JRC that will contain copies of any slides relating to the results and presented to the JRC. In addition, at BMS’ request Ambrx will transfer (within thirty (30) days of such request) to BMS all data, results, and information related to testing and studies Upon direction of the Compounds JRC, the Parties will setup and maintain a secure electronic data storage system where the Research Results will be uploaded and stored by each Party, the electronic data storage system will accessible only by the Parties (including analytical test results and non-clinical pharmacology and safety data) in the possession of Ambrx to the extent such data, results and/or information are necessary or reasonably useful for the continued Development and Commercialization of Products, including any and all Information directly relating to manufacturing methods (including related analytical methods) of the Compounds or ProductsSubcontractors as appropriate).

Disclosure of Results of Research Program. The results of all work performed by a Party the Parties as part of the Research Program shall be promptly disclosed to the other Party in a reasonable manner as such results are obtained. Ambrx Isis shall periodically provide BMS with written reports of the work performed under the Research Program and the results achieved by Isis. Isis and BMS will provide reports and analyses at each JRC meeting, and more frequently upon on reasonable request by the JRC, detailing the current status of the Research Program, including but not limited to the utilization of the Ambrx Isis FTE resources. Within thirty (30) 30 days following the end of each calendar quarterCalendar Quarter, Ambrx Isis and BMS shall each exchange and provide to the JRC a written report summarizing in reasonable detail the work performed by it under the Research Program and results achieved during the preceding calendar quarterCalendar Quarter. In addition, upon on reasonable request by a Party, the other Party will make presentations to the JRC of its activities related to in the Compounds and Products performance of the Research Program to inform such Party of the details of the work done in the performance of the Research Program. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Upon reasonable request by BMS, for purposes of supporting the Development of a Product, Ambrx Isis shall provide BMS with additional data, results and other information with respect to the work performed by Ambrx Isis in the performance of the Research Program. Any reports required under this Section 3.7 may take the form of and be recorded in minutes of the JRC that will contain copies of any slides relating to the results and presented to the JRC. In addition, at BMS’ request Ambrx Isis will transfer (within thirty (30) days of such request) to BMS all data, results, and information related to testing and studies of the Compounds (including analytical test results and non-clinical pharmacology and safety data) in the possession of Ambrx Isis to the extent such data, results and/or information are is necessary or reasonably useful for the continued Development and Commercialization of Products, including but not limited to any and all Information information directly relating to manufacturing methods (including related analytical methods) of the Compounds or Products.

Disclosure of Results of Research Program. The results of all work performed by a Party as part of the Research Program shall be promptly disclosed to the other Party in a reasonable manner as such results are obtained. Ambrx Exscientia and BMS will provide reports and analyses at each JRC JSC meeting, and more frequently upon reasonable request by the JRCJSC, detailing the current status of the Research Program, including the utilization of the Ambrx FTE resources. Within thirty (30) [****] days following the end of each calendar quarterCalendar Quarter, Ambrx Exscientia and BMS shall each exchange and provide to the JRC JSC a written report summarizing in reasonable detail the work performed by it under the Research Program and results achieved during the preceding calendar quarterCalendar Quarter. In addition, upon reasonable request by a Party, the other Party will make presentations to the JRC JSC of its activities related to the Licensed Compounds and Licensed Products to inform such Party of the details of the work done in the performance of the Research Program. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Upon reasonable request by BMS, for purposes of supporting the Development of a Licensed Product (including supporting or maintaining the Regulatory Approval for Product), Ambrx subject to and without limiting the other terms and conditions of the Agreement, Exscientia shall provide BMS with additional data, results and other information with respect to the work performed by Ambrx Exscientia in the performance of the Research Program. Any reports required under this Section 3.7 may take the form of of, and be recorded in minutes of the JRC JSC that will contain copies of of, any slides relating to the results and presented to the JRCJSC. In addition, at BMS’ request Ambrx Exscientia will transfer (within thirty (30) [****] days of such request) to BMS all data, results, and information related to testing and studies of that comprise the Compounds (including analytical test results “Licensed Compound Data Package” and non-clinical pharmacology all data, results, and safety data) information in the possession of Ambrx to the extent such data, results and/or information are necessary or reasonably useful for the continued Development and Commercialization of Products, including any and all Information directly relating to manufacturing methods (including related analytical methods) of the Compounds or ProductsLicensed Compound Data Package shall then be owned by BMS.

Disclosure of Results of Research Program. The results of all work performed by a Party as part of the Research Program shall be promptly disclosed to the other Party in a reasonable manner as such results are obtained. Ambrx uniQure and BMS will provide reports and analyses at each JRC JSC meeting, and more frequently upon reasonable request by the JRCJSC, detailing the current status of the Research Program, including the utilization of the Ambrx uniQure FTE resources. Within thirty sixty (3060) days following the end of each calendar quarterCalendar Quarter, Ambrx uniQure and BMS shall each exchange and provide to the JRC JSC a written report summarizing in reasonable detail the work performed by it under the Research Program and results achieved during the preceding calendar quarterCalendar Quarter. In addition, upon reasonable request by a Party, the other Party will make presentations to the JRC JSC of its activities related to the Compounds Therapeutics and Products to inform such Party of the details of the work done in the performance of the Research Program. The results, reports, analyses and other information regarding the Research Program disclosed by one Party to the other Party pursuant hereto may be used only in accordance with the rights granted and other terms and conditions under this Agreement. Upon reasonable request by BMS, for purposes of supporting the Development of a ProductProducts (including supporting or maintaining the Regulatory Approval for Products), Ambrx subject to and without limiting the other terms and conditions of the Agreement, uniQure shall provide BMS with additional data, results and other information Information with respect to the work performed by Ambrx uniQure in the performance of the Research Program. Any reports required under this Section 3.7 3.8 may take the form of and be recorded in minutes of the JRC JSC that will contain copies of any slides relating to the results and presented to the JRCJSC. In addition, at BMS’ request Ambrx uniQure will transfer (within thirty sixty (3060) days of such request) to BMS all data, results, and information related to testing and studies undertaken as part of the Compounds Research Program, or prior to the Effective Date with respect to any Collaboration Target or Therapeutic (including analytical test results and non-clinical pharmacology and safety data) in the possession and Control of Ambrx uniQure to the extent such data, results and/or or information are necessary or reasonably useful for the conduct of the Research Program or for the continued Development and Commercialization of Products, including any Therapeutics and all Information directly relating to manufacturing methods (including related analytical methods) of the Compounds or Products.